Granulocyte-colony stimulating factor (G-CSF) is a major cytokine that has already been clinically verified for chronic traumatic spinal cord injuries (TSCIs). In this study, the authors set out to determine the safety and efficacy of G-CSF administration for neurological and functional improvement in subacute, incomplete TSCI.
This phase II/III, prospective, double-blind, placebo-controlled, parallel randomized clinical trial was performed in 60 eligible patients (30 treatment, 30 placebo). Patients with incomplete subacute TSCIs with American Spinal Injury Association Impairment Scale (AIS) grades B, C, and D were enrolled. Patients were assessed using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scale, Spinal Cord Independence Measure (SCIM-III) and International Association of Neurorestoratology Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS), just before intervention and at 1, 3, and 6 months, after 7 daily subcutaneous administrations of 300 μg/day of G-CSF in the treatment group and placebo in the control group.
Among 60 participants, 28 patients (93.3%) in the G-CSF group and 26 patients (86.6%) in the placebo group completed the study protocol. After 6 months of follow-up, the AIS grade remained unchanged in the placebo group, while in the G-CSF group 5 patients (45.5%) improved from AIS grade B to C, 5 (45.5%) improved from AIS grade C to grade D, and 1 patient (16.7%) improved from AIS grade D to E. The mean ± SEM change in ISNCSCI motor score in the G-CSF group was 14.9 ± 2.6 points, which was significantly greater than in the placebo group (1.4 ± 0.34 points, p < 0.001). The mean ± SEM light-touch and pinprick sensory scores improved by 8.8 ± 1.9 and 10.7 ± 2.6 points in the G-CSF group, while those in the placebo group improved by 2.5 ± 0.60 and 1.2 ± 0.40 points, (p = 0.005 and 0.002, respectively). Evaluation of functional improvement according to the IANR-SCIFRS instrument revealed significantly more functional improvement in the G-CSF group (10.3 ± 1.3 points than in the placebo group (3.0 ± 0.81 points; p < 0.001). A significant difference was also observed between the 2 groups as measured by the SCIM-III instrument (29.6 ± 4.1 vs 10.3 ± 2.2, p < 0.001).
Incomplete subacute TSCI is associated with significant motor, sensory, and functional improvement after administration of G-CSF.
ABBREVIATIONSAIS = ASIA Impairment Scale; ASIA = American Spinal Injury Association; BASIR = Brain and Spinal cord Injury Research; CONSORT = Consolidated Standards of Reporting Trials; CBC = complete blood count; G-CSF = granulocyte colony-stimulating factor; IANR-SCIFRS = International Association of Neurorestoratology Spinal Cord Injury Functional Rating Scale; ISNCSCI = International Standards for Neurological Classification of Spinal Cord Injury; MAS = Modified Ashworth Scale; MPSS = methylprednisolone sodium succinate; SCIM-III = Spinal Cord Independence Measure version III; TSCI = traumatic spinal cord injury; TUMS = Tehran University of Medical Sciences; VAS = visual analog scale; WBC = white blood cell.
AnderliniPPrzepiorkaDSeongDMillerPSundbergJLichtigerB: Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion36:590–5951996
BrackenMBShepardMJHolfordTRLeo-SummersLAldrichEFFazlM: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA277:1597–16041997
DerakhshanradNSaberiHYekaninejadMSEskandariGMardaniARahdariF: Safety of granulocyte colony-stimulating factor (G-CSF) administration for postrehabilitated motor complete spinal cord injury patients: an open-label, phase I study. Cell Transplant22 (Suppl 1):S139–S1462013
FawcettJWCurtASteevesJDColemanWPTuszynskiMHLammertseD: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord45:190–2052007
FehlingsMGWilsonJRHarropJSKwonBKTetreaultLAArnoldPM: Efficacy and safety of methylprednisolone sodium succinate in acute spinal cord injury: a systematic review. Global Spine J7 (3 Suppl):116S–137S2017
GrossmanRGFehlingsMGFrankowskiRFBurauKDChowDSTatorC: A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma31:239–2552014
HawrylukGWRowlandJKwonBKFehlingsMG: Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus25(5):E142008
InadaTTakahashiHYamazakiMOkawaASakumaTKatoK: Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: analyses of follow-up cases after at least 1 year. Spine (Phila Pa 1976)39:213–2192014
ItzkovichMGelernterIBiering-SorensenFWeeksCLarameeMTCravenBC: The Spinal Cord Independence Measure (SCIM) version III: reliability and validity in a multi-center international study. Disabil Rehabil29:1926–19332007
KamiyaKKodaMFuruyaTKatoKTakahashiHSakumaT: Neuroprotective therapy with granulocyte colony-stimulating factor in acute spinal cord injury: a comparison with high-dose methylprednisolone as a historical control. Eur Spine J24:963–9672015
MontibellerGRSchackmannBUrbschatSOertelJMK: Effect of granulocyte colony-stimulating factor on the cochlear nuclei after creation of a partial nerve lesion: an experimental study in rats. J Neurosurg128:296–3032018
RingelsteinEBThijsVNorrvingBChamorroAAichnerFGrondM: Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke44:2681–26872013
SaberiHDerakhshanradNYekaninejadMS: Comparison of neurological and functional outcomes after administration of granulocyte-colony-stimulating factor in motor-complete versus motor-incomplete postrehabilitated, chronic spinal cord injuries: a phase I/II study. Cell Transplant23 (Suppl 1):S19–S232014
SakumaTYamazakiMOkawaATakahashiHKatoKHashimotoM: Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of compression myelopathy, Part 1: a phase I and IIa clinical trial. Eur Spine J21:482–4892012
SakumaTYamazakiMOkawaATakahashiHKatoKHashimotoM: Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of thoracic myelopathy: a multicenter prospective controlled trial. Spine (Phila Pa1976)37:1475–14782012
VaqueroJZuritaMRicoMABonillaCAguayoCFernándezC: Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy19:349–3592017